References

Journal Articles and Book Chapters

Arena, J. E., Weigand, S. D., Whitwell, J. L., et al. (2016). Progressive supranuclear palsy: Progression and survival. *Journal of Neurology, 263*(2), 380–389. doi:10.1007/s00415-015-7990-2

Bello-Haas, D. V. (2002). A framework for rehabilitation of neurodegenerative diseases: Planning care and maximizing quality of life. *Neurology Report, 26*(3).

Bluett, B., Pantelyat, A. Y., Litvan, I., Ali, F., Apetauerova, D., Bega, D., Bloom, L., Bower, J., Boxer, A. L., Dale, M. L., Dhall, R., Duquette, A., Fernandez, H. H., Fleisher, J. E., Grossman, M., Howell, M., Kerwin, D. R., Leegwater-Kim, J., Lepage, C., … Golbe, L. I. (2021). Best practices in the clinical management of progressive supranuclear palsy and corticobasal syndrome: A consensus statement of the CurePSP Centers of Care. *Frontiers in Neurology, 12*, 694872. doi:10.3389/fneur.2021.694872

Boxer, A. L., Yu, J. T., Golbe, L. I., Litvan, I., Lang, A. E., & Höglinger, G. U. (2017). Advances in progressive supranuclear palsy: New diagnostic criteria, biomarkers, and therapeutic approaches. *The Lancet Neurology, 16*(7), 552–563. doi:10.1016/S1474-4422(17)30157-6

Chung, D. C., Roemer, S., Petrucelli, L., & Dickson, D. W. (2021). Cellular and pathological heterogeneity of primary tauopathies. *Molecular Neurodegeneration, 16*(1), 57. doi:10.1186/s13024-021-00476-x

Cordivari, C., Misra, V. P., Catania, S., & Lees, A. J. (2001). Treatment of dystonic clenched fist with botulinum toxin. *Movement Disorders, 16*, 907–913. doi:10.1002/mds.1186

Coughlin, D. G., Dickson, D. W., Josephs, K. A., & Litvan, I. (2021). Progressive supranuclear palsy and corticobasal degeneration. In *Frontotemporal dementias* (Advances in Experimental Medicine and Biology, Vol. 1281). Springer. doi:10.1007/978-3-030-51140-1_11

Duffy, E. I., Garry, J., Talbot, L., et al. (2018). A pilot study assessing the spiritual, emotional, physical/environmental, and physiological needs of mechanically ventilated surgical intensive care unit patients via eye tracking devices, head nodding, and communication boards. *Trauma Surgery & Acute Care Open, 3*(1). doi:10.1136/tsaco-2018-000180

Eusebio, A., Koric, L., Félician, O., Guedj, E., Ceccaldi, M., & Azulay, J.-P. (2016). Progressive supranuclear palsy and corticobasal degeneration: Diagnostic challenges and clinicopathological considerations. *Revue Neurologique, 172*(8–9), 488–502. doi:10.1016/j.neurol.2016.07.009

Gaetani, L., Blennow, K., Calabresi, P., et al. (2019). Neurofilament light chain as a biomarker in neurological disorders. *Journal of Neurology, Neurosurgery & Psychiatry, 90*, 870–881.

Giannakis, A., Kloufetou, E., Pechlivani, L., et al. (2025). A review of FDG-PET in progressive supranuclear palsy and corticobasal syndrome. *International Journal of Molecular Sciences, 26*(17), 8278. doi:10.3390/ijms26178278

Goh, L., Canning, C. G., Song, J., Clemson, L., & Allen, N. E. (2023). The effect of rehabilitation interventions on freezing of gait in people with Parkinson's disease is unclear: A systematic review and meta-analyses. *Disability and Rehabilitation, 45*(19), 3199–3218. doi:10.1080/09638288.2022.2120099

Harris, G. A., Hirschfeld, L. R., Gonzalez, M. I., Pritchard, M. C., & May, P. C. (2025). Revisiting the therapeutic landscape of tauopathies: Assessing the current pipeline and clinical trials. *Alzheimer's Research & Therapy, 17*(1), 129. doi:10.1186/s13195-025-01775-x

Horie, K., Barthélemy, N. R., Spina, S., et al. (2022). CSF tau microtubule-binding region identifies pathological changes in primary tauopathies. *Nature Medicine, 28*(12), 2547–2554. doi:10.1038/s41591-022-02075-9

Kim, D. Y. (2025). Clinical framework for motor rehabilitation in parkinsonism: Integrating individualized and syndrome-specific approaches. *Brain & NeuroRehabilitation, 18*(3), e6. doi:10.12786/bn.2025.18.e6

Liu, F. T., Lu, J. Y., Li, X. Y., et al. (2023). 18F-Florzolotau PET imaging captures the distribution patterns and regional vulnerability of tau pathology in progressive supranuclear palsy. *European Journal of Nuclear Medicine and Molecular Imaging, 50*(5), 1395–1405. doi:10.1007/s00259-022-06104-0

Martinez-Valbuena, I., Emamikhah, M., Olszewska, D. A., et al. (2026). A multimodal biomarker strategy to enhance diagnostic precision in neurodegenerative parkinsonism. *Nature Medicine*. doi:10.1038/s41591-026-04398-3

Oshima, K., & Dickson, D. W. (2009). Cortical Alzheimer type pathology does not influence tau pathology in progressive supranuclear palsy. *International Journal of Clinical and Experimental Pathology, 2*(4), 399–406.

Pantelyat, A., Dayanim, G., Kang, K., Turk, B., Pagkatipunan, R., Huenergard, S. K., Mears, A., & Bang, J. (2022). Rhythmic auditory cueing in atypical parkinsonism: A pilot study. *Frontiers in Neurology, 13*, 1018206. doi:10.3389/fneur.2022.1018206

Pardini, M., Huey, E. D., Spina, S., et al. (2019). FDG-PET patterns associated with underlying pathology in corticobasal syndrome. *Neurology, 92*(10), e1121–e1135. doi:10.1212/WNL.0000000000007038

Renard, D., Collombier, L., Castelnovo, G., & Labauge, P. (2010). Teaching NeuroImages: FDG-PET in progressive supranuclear palsy. *Neurology, 74*(14), e60. doi:10.1212/WNL.0b013e3181d7d871

Rösler, T. W., Tayaranian Marvian, A., Brendel, M., et al. (2019). Four-repeat tauopathies. *Progress in Neurobiology, 180*, 101644. doi:10.1016/j.pneurobio.2019.101644

Tezuka, T., Takahata, K., Seki, M., Tabuchi, H., Momota, Y., Shiraiwa, M., Suzuki, N., Morimoto, A., Nakahara, T., Iwabuchi, Y., Miura, E., Yamamoto, Y., Sano, Y., Funaki, K., Yamagata, B., Ueda, R., Yoshizaki, T., Mashima, K., Shibata, M., … Ito, D. (2021). Evaluation of [18F]PI-2620, a second-generation selective tau tracer, for assessing four-repeat tauopathies. *Brain Communications, 3*(4), fcab190. doi:10.1093/braincomms/fcab190

Tosserams, A., Fasano, A., Gilat, M., Factor, S. A., Giladi, N., Lewis, S. J. G., Moreau, C., Bloem, B. R., Nieuwboer, A., & Nonnekes, J. (2025). Management of freezing of gait: Mechanism-based practical recommendations. *Nature Reviews Neurology, 21*(6), 327–344. doi:10.1038/s41582-025-01079-6

VandeVrede, L., Ljubenkov, P. A., Rojas, J. C., Welch, A. E., & Boxer, A. L. (2020). Four-repeat tauopathies: Current management and future treatments. *Neurotherapeutics, 17*(4), 1563–1581. doi:10.1007/s13311-020-00888-5

Wenning, G. K., Litvan, I., Jankovic, J., et al. (1998). Natural history and survival of 14 patients with corticobasal degeneration confirmed at postmortem examination. *Journal of Neurology, Neurosurgery & Psychiatry, 64*(2), 184–189. doi:10.1136/jnnp.64.2.184

Whitwell, J. L., Jack, C. R., Jr., Boeve, B. F., et al. (2010). Imaging correlates of pathology in corticobasal syndrome. *Neurology, 75*(21), 1879–1887. doi:10.1212/WNL.0b013e3181feb2e8

Zheng, Y., Cai, H., Kou, W., et al. (2026). Plasma tau-species positive neuron-derived extracellular vesicles in progressive supranuclear palsy. *Brain*, awag091. doi:10.1093/brain/awag091

Additional References Identified From the Shorthand Citations

Alquezar, C., Arya, S., & Kao, A. W. (2021). Tau post-translational modifications: Dynamic transformers of tau function, degradation, and aggregation. *Frontiers in Neurology, 11*, 595532. doi:10.3389/fneur.2020.595532

Armstrong, M. J., Litvan, I., Lang, A. E., Bak, T. H., Bhatia, K. P., Borroni, B., Boxer, A. L., Dickson, D. W., Grossman, M., Hallett, M., Josephs, K. A., Kertesz, A., Lee, S. E., Miller, B. L., Reich, S. G., Riley, D. E., Tolosa, E., Tröster, A. I., Vidailhet, M., & Weiner, W. J. (2013). Criteria for the diagnosis of corticobasal degeneration. *Neurology, 80*(5), 496–503. doi:10.1212/WNL.0b013e31827f0fd1

Höglinger, G. U., Respondek, G., Stamelou, M., Kurz, C., Josephs, K. A., Lang, A. E., Mollenhauer, B., Müller, U., Nilsson, C., Whitwell, J. L., Arzberger, T., Englund, E., Gelpi, E., Giese, A., Irwin, D. J., Meissner, W. G., Pantelyat, A., Rajput, A., van Swieten, J. C., … Litvan, I. (2017). Clinical diagnosis of progressive supranuclear palsy: The Movement Disorder Society criteria. *Movement Disorders, 32*(6), 853–864. doi:10.1002/mds.26987

Parra Bravo, C., Naguib, S. A., & Gan, L. (2024). Cellular and pathological functions of tau. *Nature Reviews Molecular Cell Biology, 25*, 845–864. doi:10.1038/s41580-024-00753-9

Rojas, J. C., Bang, J., Lobach, I. V., Tsai, R. M., Rabinovici, G. D., Miller, B. L., & Boxer, A. L. (2018). CSF neurofilament light chain and phosphorylated tau 181 predict disease progression in PSP. *Neurology, 90*(4), e273–e281. doi:10.1212/WNL.0000000000004859

Shi, Y., Zhang, W., Yang, Y., Murzin, A. G., Falcon, B., Kotecha, A., van Beers, M., Tarutani, A., Kametani, F., Garringer, H. J., Vidal, R., Hallinan, G. I., Lashley, T., Saito, Y., Murayama, S., Yoshida, M., Tanaka, H., Kakita, A., Ikeuchi, T., … Scheres, S. H. W. (2021). Structure-based classification of tauopathies. *Nature, 598*, 359–363. doi:10.1038/s41586-021-03911-7

Image

Yokoyama, M., Kobayashi, H., Tatsumi, L., & Tomita, T. (2022). *Tau isoforms in the human brain* [Diagram]. Wikimedia Commons. Original image from *Mouse models of Alzheimer's disease*, *Frontiers in Molecular Neuroscience, 15*, 912995.

Organizations, Websites, and Patient Resources

Aphasia Community. (n.d.). *Life participation approach to aphasia.*

Aspire. (n.d.). *EMST150.*

Association for Frontotemporal Degeneration. (n.d.). *The Association for Frontotemporal Degeneration (AFTD).*

Brain Support Network. (n.d.). *Brain Support Network.*

Cleveland Clinic. (2013). *Pseudobulbar affect (PBA).*

CurePSP. (n.d.). *CurePSP.*

ElevenLabs. (2024). *ElevenLabs: Generative AI text to speech and voice cloning.*

Goblin Tools. (2025). *Magic ToDo.*

International Dysphagia Diet Standardisation Initiative. (n.d.). *IDDSI framework documents.*

Lingraphica. (2025). *What is AAC?*

Louizos, L. (2025). *Understanding eye issues in progressive supranuclear palsy (PSP).* CCF Coleen Cunningham Foundation.

Mission MSA. (n.d.). *Mission MSA.*

Parkinson Voice Project. (n.d.). *Speech therapy for people with Parkinson's.*

Parkinson's Foundation. (n.d.). *Parkinson's Foundation.*

Power for Parkinson's. (n.d.). *Power for Parkinson's* [YouTube channel].

PWR!Moves. (n.d.). *PWR!Moves.*

RAZ Mobility. (n.d.). *Next generation assistive technology.*